Literature DB >> 19340423

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.

Rosa Mendez1, Natalia Aptsiauri, Ana Del Campo, Isabel Maleno, Teresa Cabrera, Francisco Ruiz-Cabello, Federico Garrido, Angel Garcia-Lora.   

Abstract

Altered HLA class I and class II cell surface expression has been reported in many types of malignancy and represents one of the major mechanism by which tumour cells escape from T lymphocytes. In this report, we review the results obtained from the study of constitutive and IFN-gamma-induced expression of HLA class I and II molecules in 91 human melanoma cell lines from the European Searchable Tumour Cell Line Database, and compare them with published data on HLA expression in other types of cancer. Various types of alterations in HLA class I cell surface expression were found in a high percentage (67%) of the studied cell lines. These alterations range from total to selective HLA class I loss and are associated with beta2-microglobulin gene mutations, transcriptional downregulation of HLA class I genes and antigen processing machinery components, or with the loss of heterozygosity in chromosome 6. The most frequently observed phenotype is selective downregulation of HLA-B locus, reversible after treatment with IFN-gamma. The expression of constitutive- or IFN-gamma induced-surface expression of at least one HLA class II locus is positive in 71.5% of the analysed cell lines. Four different HLA class II expression phenotypes were defined, and a positive correlation between the expression of class I and II molecules is discussed. More detailed information on the HLA expression patterns and others immunological characteristics of these melanoma cell lines can be found on the following website http://www.ebi.ac.uk/ipd/estdab .

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19340423     DOI: 10.1007/s00262-009-0701-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.

Authors:  Sheila López-Cobo; Natalia Pieper; Carmen Campos-Silva; Eva M García-Cuesta; Hugh T Reyburn; Annette Paschen; Mar Valés-Gómez
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

Review 2.  Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

Authors:  Elizabeth H Byrne; David E Fisher
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

3.  The Immunogenetics of Non-melanoma Skin Cancer.

Authors:  Sabha Mushtaq
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.

Authors:  Claire Y Oh; Martin G Klatt; Christopher Bourne; Tao Dao; Megan M Dacek; Elliott J Brea; Sung Soo Mun; Aaron Y Chang; Tatyana Korontsvit; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2019-09-20       Impact factor: 11.151

5.  Distinct MHC gene expression patterns during progression of melanoma.

Authors:  Yan Degenhardt; Jia Huang; Joel Greshock; Galene Horiates; Katherine Nathanson; Xiaolu Yang; Meenhard Herlyn; Barbara Weber
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

Review 6.  Genetics of primary intraocular tumors.

Authors:  Nisha Nagarkatti-Gude; Yujuan Wang; Mohammad Javed Ali; Santosh G Honavar; Martine J Jager; Chi-Chao Chan
Journal:  Ocul Immunol Inflamm       Date:  2012-08       Impact factor: 3.070

7.  Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.

Authors:  Tiziano Di Tomaso; Stefania Mazzoleni; Ena Wang; Gloria Sovena; Daniela Clavenna; Alberto Franzin; Pietro Mortini; Soldano Ferrone; Claudio Doglioni; Francesco M Marincola; Rossella Galli; Giorgio Parmiani; Cristina Maccalli
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

8.  Killer cell immunoglobulin-like receptor gene associations with autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms.

Authors:  Piotr Kuśnierczyk
Journal:  Front Immunol       Date:  2013-01-29       Impact factor: 7.561

9.  Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.

Authors:  Mohammad Hojjat-Farsangi; Fatemeh Ghaemimanesh; Amir Hossein Daneshmanesh; Ali-Ahmad Bayat; Jafar Mahmoudian; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Hakan Mellstedt
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.